Bioxcel therapeutics reports second quarter 2023 financial results and announces strategic reprioritization

B usiness to prioritize high- potential agitation market opportunities for bxcl501 in bipolar disorders, schizophrenia, and alzheimer's disease

BTAI Ratings Summary

BTAI Quant Ranking